We are live on ! Find out more

Biomerica

BMRA

Market cap $10.6M

2.32 USD

-0.14

5.69%

At close Updated Sep 25, 4:00 PM EDT

1 day

-5.69%

5 days

-9.02%

1 month

31.07%

3 months

32.57%

6 months

7.41%

Year to date

-8.3%

1 year

-17.14%

5 years

-94.18%

10 years

-89.75%

About: Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America generating key revenue from North American Markets.

Employees: 50

Healthcare Medical Devices

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

Biomerica Reports Fiscal 2026 Year-End Financial Results

IRVINE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA) today reported its financial results for the fiscal year ended May 31, 2026 (“Fiscal 2026”).

Biomerica Reports Fiscal 2026 Year-End Financial Results

Biomerica Announces $2.23 Million Financing

IRVINE, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (“Biomerica” or the “Company”), a developer and manufacturer of diagnostic test systems, today announced that it has entered into definitive agreements with institutional and individual investors for a private placement of 1,393,705 unregistered shares of the Company's common stock at a price of $1.60 per share, expected to provide approximately $2.23 million in gross proceeds to the Company.

Biomerica Announces $2.23 Million Financing

Biomerica Lands a $1.75 Million CDMO Master Services Agreement for IVD Diagnostic Development

Auto-renewing Master Services Agreement engages Biomerica's integrated development and manufacturing platform, reflecting the Company's CDMO strategy as a capital-efficient, parallel revenue stream alongside its core inFoods® IBS program Auto-renewing Master Services Agreement engages Biomerica's integrated development and manufacturing platform, reflecting the Company's CDMO strategy as a capital-efficient, parallel revenue stream alongside its core inFoods® IBS program

Biomerica Lands a $1.75 Million CDMO Master Services Agreement for IVD Diagnostic Development

Biomerica's inFoods® IBS Data Accepted for Presentation at Digestive Disease Week 2026

Real-world clinical experience with the novel IBS-specific guided diagnostic therapy to be presented at the world's largest GI medical conference, May 2–5, 2026, in Chicago Real-world clinical experience with the novel IBS-specific guided diagnostic therapy to be presented at the world's largest GI medical conference, May 2–5, 2026, in Chicago

Biomerica's inFoods® IBS Data Accepted for Presentation at Digestive Disease Week 2026

Biomerica Announces Medicare Administrative Contractor Confirmation of Individual Claim Review for inFoods® IBS, Opening a Scalable Medicare Commercialization Pathway

Company and Laboratory Partner Believe Properly Documented Claims Are Positioned for Payment Under Existing $300 CMS Reimbursement Rate Company and Laboratory Partner Believe Properly Documented Claims Are Positioned for Payment Under Existing $300 CMS Reimbursement Rate

Biomerica Announces Medicare Administrative Contractor Confirmation of Individual Claim Review for inFoods® IBS, Opening a Scalable Medicare Commercialization Pathway

Biomerica Launches inFoods® IBS in Canada Through Partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs

— Represents Biomerica's First Commercial Entry into the Canadian Market for its Precision, Diagnostic-Guided Therapy — Canada Has One of the Highest IBS Prevalence Rates in the World — an Estimated 18% vs. 11% Globally — Up to Five Million Canadians May Have IBS, Representing a Significant and Underserved Market Opportunity

Biomerica Launches inFoods® IBS in Canada Through Partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs

Biomerica Reports Third Quarter Fiscal 2026 Financial Results

IRVINE, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (“Biomerica” or the “Company”) a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the third quarter of fiscal 2026 ended February 28, 2026.

Biomerica Reports Third Quarter Fiscal 2026 Financial Results

Biomerica Receives First Commercial Order for its H. pylori test (Hp Detect™) from One of the Largest Clinical Laboratory Chains in Europe

IRVINE, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical diagnostic and therapeutic products, today announced it has received its first commercial order for Hp Detect™, its Helicobacter pylori (H. pylori) diagnostic stool antigen test, from one of the largest clinical laboratory chains operating across Europe. The initial order is for the United Kingdom market, where Hp Detect™ received registration from the UK Medicines and Healthcare products Regulatory Agency (MHRA) in February 2026.

Biomerica Receives First Commercial Order for its H. pylori test (Hp Detect™) from One of the Largest Clinical Laboratory Chains in Europe

Biomerica Receives MHRA Registration for hp+detect™, Allowing Commercial Sales in Great Britain

UK Market Entry: MHRA registration authorizes hp+detect™ for commercial sale in Great Britain Active Commercialization: Biomerica is in active discussions with UK partners to access the diagnostic laboratory market and expects to provide further updates as agreements are finalized. Disease Burden: The WHO designates H.

Biomerica Receives MHRA Registration for hp+detect™, Allowing Commercial Sales in Great Britain

Biomerica Reports Real-World Data: Nearly 60% of IBS Patients Achieved Clinically Meaningful Pain Reduction and 68% Achieved Bloating Reduction with the inFoods® IBS Therapy

Key Highlights Responder Analysis: 59.4% of patients achieved ≥30% reduction in abdominal pain; 68.1% achieved ≥30% reduction in bloating—using the FDA-recognized responder endpoint consistent with the Company's peer-reviewed randomized controlled trial. CMS Payment Rate: $300 national Medicare payment rate established, effective January 1, 2026.

Biomerica Reports Real-World Data: Nearly 60% of IBS Patients Achieved Clinically Meaningful Pain Reduction and 68% Achieved Bloating Reduction with the inFoods® IBS Therapy

See News Rankings

Price charts implemented using Lightweight Charts™